alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32

CERTIFICATIONS PURSUANT TO SECTION
906OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report
on Form 10-K of NovaMed, Inc. (the Company) for the fiscal year ended December
31, 2005 as filed with the Securities and Exchange Commission on the date hereof
(the Report), I, Thomas S. Hall, Chief Executive Officer of the Company,
certify, pursuant to section 906 of the Sarbanes-Oxley Act of 2002,
that:

| | (1) |  | the Report fully complies with
      the requirements of section 13(a) or 15(d) of the Securities Exchange Act
      of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
| |    
| | (2) |  | the information contained in the
      Report fairly presents, in all material respects, the financial condition
      and results of operations of the Company.
| |    
| |    

|/s/
      Thomas S. Hall | 
|------------------------ | 
|Thomas S. Hall          
|Chief Executive Officer 
|April 28, 2006          

In connection with the Annual Report
on Form 10-K of NovaMed, Inc. (the Company) for the fiscal year ended December
31, 2005 as filed with the Securities and Exchange Commission on the date hereof
(the Report), I, Scott T. Macomber, Chief Financial Officer of the Company,
certify, pursuant to section 906 of the Sarbanes-Oxley Act of 2002,
that:

| | (1) |  | the Report fully complies with
      the requirements of section 13(a) or 15(d) of the Securities Exchange Act
      of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
| |    
| | (2) |  | the information contained in the
      Report fairly presents, in all material respects, the financial condition
      and results of operations of the Company.
| |    
| |    

|/s/
      Scott T. Macomber | 
|--------------------------- | 
|Scott T. Macomber          
|Chief Financial Officer    
|April 28, 2006             

This certification
accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 and shall not be deemed filed by the Company for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended.

---
, C.J.

this court's discretion. Smith v. Eighth Judicial Dist. Court, 107 Nev. 674, 677, 818 P.2d 849, 851 (1991). It is petitioners' burden to demonstrate that this court's extraordinary intervention is warranted. Pan v. Eighth Judicial Dist. Court, 120 Nev. 222, 228, 88 P.3d 840, 844 (2004).

Having considered the petition and appendix, we conclude that writ relief is not merited. See Smith, 107 Nev. at 677, 818 P.2d at 851. Accordingly, we deny the petition. See NRAP 21(b)(1).

It is so ORDERED.



# Pieike4 

# tli p Pickering

Saitta MOM J.

cc: Hon. Timothy C. Williams, District Judge Bartlit Beck Herman Palenchar & Scott LLP Holland & Hart LLP/Las Vegas Weinberg, Wheeler, Hudgins, Gunn & Dial, LLC Lewis Roca Rothgerber LLP/Las Vegas Eglet Law Group Kemp, Jones & Coulthard, LLP Eighth District Court Clerk

2
TOCIOI,A T"\''1-Ul,A}-ONO

Ootcruor

li\OrlA. SUNIA

I.l, Gorcrnor

AI\{BRICAN SAI\{OA ENVIRONMENTAL PROTECTION AGENCY

P.O. Dox PPA

Pago Pago,Anrcrican Samoa 96799

TOAF,\ T.'I" VAIACAE I'II.D.

I)irccl0r

I'honc: (68{) 633-230{

Adnrirr. l'ar: (68{) 633-5715

Progrunrs Frx: (68J) 613-580f

10 December 2010

David W. Smith

NPDES Permits Office

USEPA Region 9 (WTR-S)

75 Hawthorne Street

San Francisco, CA 94i05

Re: CWA Section 401 Water Quatity Certification - Pesticide General Permit for Point

Source Discharges from the Application of Pesticides

Dear Mr. Smith,

The American Samoa Environmental Protection Agency (AS-EPA) has received and reviewed

your request for a Water Quality Certification for the National Pollutant Discharge Elimination

System O{PDES) Pesticide General Permit for Point Source Discharges from the Application of

Pesticides.

The activity, as described (see draft NPDES Pesticide General Permit and Draft Fact Sheet

provided November 2010), is found to be consistent with the protected uses for fresh surface

waters, as stated in the American Samoa Water Quality Standards (ASWQS) and sections

208(e), 301, 302,303, 306, and 307 of the Clean Water Act (CWA). Certification is hereby

given for this activity, provided that the ASWQS continue to be met.

If you have any questions regarding this certification, please feel free to contact LCDR Matt

Vojik of my staff at (684) 633-2304.

Sincerelv.

Fa'amao Asalele, Assistant Director - Technical Programs

LCDR Matt Vojik, P.E., Technical Services Manager

Will Sili, Air and Land Program Manager
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 3131 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 3131

             To suspend temporarily the duty on imdaziflam.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 10, 2012

  Mrs. Hagan introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
             To suspend temporarily the duty on imdaziflam.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. IMDAZIFLAM.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      N-[(1R,2S)-2,3-     Free         No change        No change        On or before 12/  ''.
                        dihydro-2,6-                                                       31/2015.......
                        dimethyl-1H-inden-
                        1-yl]-6-(1-
                        fluoroethyl)-
                        1,3,5-triazine-
                        2,4-diamine
                        (imdaziflam) (CAS
                        No. 950782-86-2)
                        (provided for in
                        subheading
                        3808.93.15)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
7877745526 12:10:30 p.m. 09-13-2011 1 .'1 

U.S. Department of Transportation „ .,_, ^„ . •[-KI T r\r 

Office of «ii6 Secretary of Transportation .;/'111 l.'iCH I U r 

DESIGNATION OF AGENT FOR :;".! JSFORTATION 

SERVICE OF NOTICE, PROCESS, ORDERS . '''-ri OPERATIONS 

DECISIONS, OPERATIONS SPECIFICATIONS AND OTHER REQUIREMENTS 

, , , ^A\ SEP ?0 A S: 32 

Federal Aviation Administration 

South Florida FSDO-19 

La Torre de Plaza Las Americas 

525 F,D. Roosevelt Ave, Suite 901 

San Juan, P.R. 00918-1198 

Dorado Aviation. Inc. ^ having its principal office at 

(Name of Company, please print) 

Isia Grande Airport. South Access Road, Tropical Aviation Terminal Building. San Juan, P.R. 00936 

(Address) 

hereby designates, pursuant to section 46103 and 41302 of Title 49 of the U.S. Code, as amended, the 

person named below as its Agent upon service of all notice, process, all orders, decisions, and 

requirements of the Department of Transportation may be made for and on behalf of said carrier, 

hereby canceling ail previous designations of agents made by it to the FAA, DOT or Board. The person 

named below is authorized to sign for and agree to the Operations Specifications, issued to the above 

mentioned company, governing flight operations into the United States. 

Name of Agent: Luis A. iritarry, L. A. Irizarrv & Associates. Inc. 

(Please Print) 

Address: PO Box 37217. San Juan. Puerto Rico 00937-0217 

Phone Number (787) 752-7621 Fax Number: (787) 276-3846 Email: irizarrv@icenetworks.com 

The Agent so desiEoaJed has signed his name anjLalso his initials in the following space: 

Name; / ^ f/V""' ^ J-"''^^ J (lnitials)_ 

^ 

IN WITNESS WHEREOF, Dorado Aviation. Inc. has caused these presents to be signed in its 

(Name of Company) 

name by, Ricardo Gonzalez , President of said company, 

(Please Print) 

and to be attested under its corporate seal by Dorado Aviation. Inc.. General Manager 

(SecretaiY or other Title) 

on this 12"^ dav of September. 2011. 

Dorado Aviation. Inc 

ATTEST: 

(Secretary or other officer)
<PAGE>

                                                                    Exhibit 99.1
                                                                    ------------

                              AmericasDoctor, Inc.
                        1325 Tri-State Parkway, Suite 300
                             Gurnee, Illinois 60031

                                 March 26, 2002

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC  20549

Re:  Confirmation of Arthur Andersen Representations

Ladies and Gentlemen:

         Pursuant to Temporary Note 3T to Article 3 of Regulation S-X, Arthur
Andersen LLP ("Andersen") has represented the following to us in its letter
               --------
dated March 26, 2002:

         (1)      the audit of AmericasDoctor, Inc.'s financial statements for
                  the fiscal year ended December 31, 2001 (the "Audit") was
                                                                -----
                  subject to Andersen's quality control system for the U.S.
                  accounting and auditing practice to provide reasonable
                  assurance that the Audit was conducted in compliance with
                  professional standards;

         (2)      the Audit was conducted with an appropriate continuity of
                  Andersen  personnel and

         (3)      the Audit was conducted with an appropriate level of
                  consultation from Andersen's national office.


Availability of personnel at foreign affiliates of Andersen is not relevant to
the Audit.

                                           Very truly yours,


                                           AmericasDoctor, Inc.

                                           /s/ David R. Adamoli
                                           -------------------------------------
                                           David R. Adamoli
                                           Chief Financial Officer and Secretary
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 06-6094 

ANTHONY J. TURNER,

Petitioner - Appellant,

versus

GENE M. JOHNSON, Director, Virginia Department

of Corrections,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern

District of Virginia, at Norfolk. Robert G. Doumar, Senior

District Judge. (2:05-cv-00683-RGD)

Submitted: May 18, 2006 Decided: May 31, 2006

Before WIDENER and WILKINSON, Circuit Judges, and HAMILTON, Senior

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Anthony J. Turner, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Anthony J. Turner, a Virginia inmate, seeks to appeal the

district court’s order dismissing without prejudice his petition

filed under 28 U.S.C. § 2254 (2000) as an unauthorized second or

successive petition. The order is not appealable unless a circuit

justice or judge issues a certificate of appealability. 28 U.S.C.

§ 2253(c)(1) (2000); Jones v. Braxton, 392 F.3d 683 (4th Cir.

2004). A certificate of appealability will not issue absent “a

substantial showing of the denial of a constitutional right.” 28

U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by

demonstrating that reasonable jurists would find the district

court’s assessment of his constitutional claims debatable and that

any dispositive procedural rulings by the district court are also

debatable or wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336

(2003); Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee,

252 F.3d 676, 683 (4th Cir. 2001). We have independently reviewed

the record and conclude that Turner has not made the requisite

showing. Accordingly, we deny a certificate of appealability, and

dismiss the appeal. We dispense with oral argument because the

facts and legal contentions are adequately presented in the

materials before the court and argument would not aid the

decisional process.

DISMISSED
Exhibit 4.3

 

CONSENT OF COUNSEL

 

To:  The Directors of Agnico-Eagle

 

We hereby consent to the use of our name under the heading “Other Matters Related to the Offer — Legal Matters” and to the reference to our name and opinion contained under “Certain Canadian Federal Income Tax Considerations” in the Circular accompanying the Offer dated October 13, 2011 made by Agnico-Eagle to the Shareholders, which Circular is included in the Agnico-Eagle Registration Statement on Form F-80 being filed under the United States Securities Act of 1933, as amended.

 

 

	
 
    	
 
    	
/s/ Davies Ward Phillips & Vineberg   LLP
    
	
 
    	
 
    	
DAVIES WARD PHILLIPS & VINEBERG LLP
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Toronto, Ontario, Canada
    	
 
    	
 
    
	
October 13, 2011
<Page>

                                                                    EXHIBIT 23.1

                      [LETTERHEAD OF HJ & ASSOCIATES, LLC]

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors
National Health Partners, Inc.
Horsham, PA

We consent to the incorporation by reference in the registration statements on
Form S-8 of National Health Partners, Inc., Registration Nos. 333-131379 and
333-131589, of our report dated March 16, 2007, with respect to the consolidated
balance sheet of National Health Partners, Inc. and Subsidiary as of December
31, 2006 and the related consolidated statements of operations, stockholders'
equity (deficit) and cash flows for the years ended December 31, 2006 and 2005,
which report appears in the Annual Report on Form 10-KSB of National Health
Partners, Inc. for its fiscal year ended December 31, 2006.


/s/ HJ & Associates, LLC

HJ & Associates, LLC
Salt Lake City, Utah
March 16, 2007
II 

112TH CONGRESS 

2D SESSION S. 3087 

To suspend temporarily the duty on acrylic filament tow containing 85 percent 

or more by weight of acrylonitrile units and 2 percent or more but 

not over 3 percent of water, colored, crimped, with an average decitex 

of 3.3 (plus or minus 10 percent) and an aggregate filament measure 

in the tow bundle between 660,000 and 1,200,000 decitex, with a length 

greater than 2 meters. 

IN THE SENATE OF THE UNITED STATES 

MAY 10, 2012 

Mrs. HAGAN introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on acrylic filament tow 

containing 85 percent or more by weight of acrylonitrile 

units and 2 percent or more but not over 3 percent 

of water, colored, crimped, with an average decitex of 

3.3 (plus or minus 10 percent) and an aggregate filament measure in the tow bundle between 660,000 and 

1,200,000 decitex, with a length greater than 2 meters. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ebenthall on DSK5SPTVN1PROD with BILLS
2 

•S 3087 IS

1 SECTION 1. ACRYLIC FILAMENT TOW CONTAINING 85 PER2 CENT OR MORE BY WEIGHT OF ACRYLO3 NITRILE UNITS AND 2 PERCENT OR MORE 

4 BUT NOT OVER 3 PERCENT OF WATER, COL5 ORED, CRIMPED, WITH AN AVERAGE DECITEX 

6 OF 3.3 (PLUS OR MINUS 10 PERCENT) AND AN 

7 AGGREGATE FILAMENT MEASURE IN THE 

8 TOW BUNDLE BETWEEN 660,000 AND 1,200,000 

9 DECITEX, WITH A LENGTH GREATER THAN 2 

10 METERS. 

11 (a) IN GENERAL.—Subchapter II of chapter 99 of 

12 the Harmonized Tariff Schedule of the United States is 

13 amended by inserting in numerical sequence the following 

14 new heading: 

‘‘ 9902.01.00 Acrylic filament tow containing 85 percent or more 

by weight of acrylonitrile 

units and 2 percent or more 

but not over 3 percent of 

water, colored, crimped, with 

an average decitex of 3.3 

(plus or minus 10 percent) 

and an aggregate filament 

measure in the tow bundle 

between 660,000 and 

1,200,000 decitex, with a 

length greater than 2 meters 

(provided for in subheading 

5501.30.00) ........................... Free No change No change On or before 

12/31/2015 ’’. 

15 (b) EFFECTIVE DATE.—The amendment made by 

16 subsection (a) applies to goods entered, or withdrawn from 

17 warehouse for consumption, on or after the 15th day after 

18 the date of the enactment of this Act. 

Æ 


ebenthall on DSK5SPTVN1PROD with BILLS
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

Annual Report Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
for the fiscal year ended December 31, 1999

Commission File Number: 333-66805-03

NationsLink Funding Corporation issuer in respect of
Commercial Mortgage Pass-Through Certificates Series 1999-SL
(Exact Name of registrant as specified in its charter)

Delaware      			99-637747
(State or Other Juris-		(I.R.S. Employer
diction of Incorporation)     Identification No.)

100 North Tyron Street, Charlotte, NC 28255
(Address of Principal Executive Office)

704-386-2400
(Registrant's telephone number, including area code)


Securities registered pursuant to Section 12(b) of the
Act:     None

Securities registered pursuant to Section 12(g) of the
Act:     None

Indicate by check mark whether the registrant (1) has filed all
reports required to be filed  by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

Yes  X   No _

Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K is not contained herein,
and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements
incorporated by reference in part III of this Form 10-K or any
amendment to this Form 10-K.

Not applicable.

Aggregate market value of voting stock held by non-affiliates of
the Registrant as of December 31, 1999.

Not applicable.

Number of shares of common stock outstanding as of December 31,
1999.

Not applicable.
Variable Compensation Plan



 Exhibit 10.5 
 Varolii Executive Variable Compensation – 2008 
 At Varolii, all executive-level individuals have a portion of
their total compensation structured as variable compensation, i.e., it is “at risk” and tied to company performance. This compensation program is a key element of Varolii’s performance management process and contributes to the success
of our employees and company. 
 Plan Design 
  

	 	•	 	 Target pay-outs: Each individual has a specific target pay-out, which is typically a percentage of their base pay. Executive-level targets range from a
percentage of base salary to a flat dollar amount (typically in the 20% to 50% range, annualized). The variable compensation target will be communicated to the executive after completion of the annually salary review 


  

	 	•	 	 Review periods: There are two review periods for the Executive variable compensation program: 


  

	 	•	 	 1st half (Q1/Q2) 


  

	 	 •
	 	 2nd half (Q3/Q4)



 The above targets (“target pay-outs”) are annualized.
The target pay-out for each review period is 50% of the total target, e.g., for an Executive with a 20% target bonus, they have a 10% potential target pay-out for the 1st and 2nd half review periods. 
  

	 	•	 	 Company performance: 100% of the target pay-out is tied to company performance. Specifically, company targets are set and agreed upon with the compensation
committee and communicated prior to the plan year. 


 2008 Performance factors: 
  

				
	 Performance Factors
	  	Factor weighting	 
	 Total revenue vs. target, leveraged
	  	50	%
	 Pro Forma Operating Inc (loss) vs. target, leveraged
	  	50	%

  

	 	•	 	 Timing and Pay-outs: Bonuses are paid out semi-annually, typically on the first pay period in August and February each year.
Exhibit 99.8

CONSENT OF APPOINTED ACTUARY

I hereby consent to the use and incorporation by reference in this Annual Report on Form 40-F of Manulife Financial Corporation (the
Company) for the year ended December 31, 2013 of my Appointed Actuarys Report to the Shareholders and Directors dated February 26, 2014 (the Report), relating to the valuation of the policy liabilities of the
Company for its Consolidated Balance Sheets as at December 31, 2013 and 2012 and their change in the Consolidated Statements of Operations for the years then ended.



|                                          
|------------------------------------------
|/s/ Cindy L. Forbes                       
|Cindy L. Forbes                           
|Executive Vice President and Chief Actuary
|Fellow, Canadian Institute of Actuaries   
|Toronto, Canada                           

Date: February 26, 2014
### CertificationStatement

I, Gerald D

. Reid, Assistant Attorney General, hereby certify that the Maine State Implmentation Plan for Regional Haze contained in the attached State Implementation (SIP) submittals has been adopted in accordance withall governing requirements ofthe Maine Administrative Procedures Act and was lawfully adopted by the Board of Environmental Protection on December 2, 2010 . 

### ~l~'m

~~-2"'- 1212110 T 7 Gerald D

. Reid,A .A.G. Date
II 

112TH CONGRESS 

2D SESSION S. 3024 

To extend the temporary suspension of duty on Cyfluthrin. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on Cyfluthrin. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CYFLUTHRIN. 

4 (a) IN GENERAL.—Heading 9902.10.67 of the Har5 monized Tariff Schedule of the United States (relating to 

6 Cyfluthrin) is amended by striking the date in the effective 

7 period column and inserting ‘‘12/31/2015’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies with respect to goods entered, or 

10 withdrawn from warehouse for consumption, on or after 

11 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS
Order entered November 16, 2022

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-22-00634-CV

IN THE INTEREST OF V.W. JR., A CHILD

On Appeal from the 196th Judicial District Court

Hunt County, Texas

Trial Court Cause No. 90770

ORDER

Before us is the Texas Department of Family and Protective Services’s

motion for extension of time to file its appellee’s brief. Because these types of 

appeals must be handled expeditiously, the Department’s motion is GRANTED 

IN PART. See TEX. R. JUD. ADMIN. 6.2(a) (appeal of child protection case should, 

so far as reasonably possible, be disposed of within 180 days of the date the notice 

of appeal is filed). The Department’s brief is now due to be filed on or before 

November 23, 2022. 

/s/ AMANDA L. REICHEK

PRESIDING JUSTICE